Moffitt Cancer Center
Moffitt is dedicated to one lifesaving mission: to contribute to the prevention and cure of cancer. The Tampa-based facility is one of only 57 National Cancer Institute-designated Comprehensive Cancer Centers, a distinction that recognizes Moffitt’s scientific excellence, multidisciplinary research, and robust training and education. Moffitt’s expert nursing staff is recognized by the American Nurses Credentialing Center with Magnet® status, its highest distinction. With more than 8,000 team members, Moffitt has an economic impact in the state of $2.4 billion. For more information, call 1-888-663-3488, visit MOFFITT.org, and follow the momentum on Facebook, Twitter, Instagram and YouTube.
The ImmunoVerse: (Ep. 9) The Science That’s Changing Pancreatic Cancer with Dr. Robert Vonderheide
An Insider's Look: Innovations in Skin Cancer Research
Ann Klein - It Broke My Heart In Beautiful Pieces
Moffitt Cancer Center’s 2025 Veterans Day Ceremony
The ImmunoVerse: (Ep. 8) LIVE from the 2025 SITC Annual Meeting, ft. Sandra Demaria, MD
Greg Sawyer, PhD & Patrick Hwu, MD: How Moffitt Uses Microscopy To Study Immune & Cancer Cells
Kenneth Tsai, MD, PhD on Pathway-Synthenic Senescence as a Means to Augment Immunotherapy Response
Drs. Peter Forsyth & Patrick Hwu Discuss the Latest Immunotherapy Research for the Treatment of LMD
Mihaela Druta, MD Presents Data for Mecbotamab Vedotin, an AXL-Targeting ADC, in Soft Tissue Sarcoma
Drs. Daniel Abate-Daga and Patrick Hwu Discuss Testing CAR-TIL Cells
Kenneth Tsai, MD: Phase 2 VP-315 Immune Activation in Basal Cell Carcinoma & Non-Surgical Options
Christopher Polera How RAS Inhibition Reshapes The Tumor Immunopeptidome To Reveal New Immune Target
Fatema Khambati on How Enrichment of Neoantigen-Reactive TILs Offers New Insight into Bladder Cancer
Drs. Andreas Saltos & Greg Sawyer on Using Oncolytic Viruses to Enhance Immunotherapy for NSCLC
Kenneth Tsai, MD: Phase 2 57.7% pCR w/ Lenvatinib + Pembrolizumab in Stage 3-4 Merkel Cell Carcinoma
Alex Jaeger, PhD and Greg Sawyer, PhD Discuss the Immunopeptidome, MHC-I and MHC-II
David Nusbaum, MD on Phase I Trial: Autologous TIL Therapy for BCG-Exposed Bladder Cancer
Drs. Greg Sawyer, Patrick Hwu & Fred Locke on Moffitt’s Nikon Instruments Center of Excellence Work
Dr. Mihaela Druta Welcome Message to SITC 2025
Meet the Experts AYA Edition: Life After Cancer Survivorship Clinic
Meet the Experts AYA Edition: Navigating Body Image and Self Worth as a Young Adult Patient
Meet the Experts: Su equipo médico la función de su trabajador social (Role of Your Social Worker)
Live: Ask the Experts - Lung Cancer Awareness Month
Онкологический центр Моффитта: создан специально для борьбы с раком (60_Social)
5 лет преобразований — онкологический центр Моффитта